These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32565905)

  • 1. COVID-19: hypofractionation in the Radiation Oncology Department during the 'state of alarm': first 100 patients in a private hospital in Spain.
    Larrea L; López E; Antonini P; González V; Berenguer MÁ; Baños MC; Bea J; Domingo J
    Ecancermedicalscience; 2020; 14():1052. PubMed ID: 32565905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial.
    Wortel RC; Pos FJ; Heemsbergen WD; Incrocci L
    J Sex Med; 2016 Nov; 13(11):1695-1703. PubMed ID: 27665195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.
    Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):823-833. PubMed ID: 30458234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
    McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
    Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
    Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
    Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are We Choosing Wisely in Radiation Oncology Practice-Findings From an Australian Population-Based Study.
    Ong WL; Foroudi F; Milne RL; Millar JL
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1012-1016. PubMed ID: 30981834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Practice evolution of hypofractionation in breast radiation therapy and medical impact].
    Dupin C; Vilotte F; Lagarde P; Petit A; Breton-Callu C
    Cancer Radiother; 2016 Jun; 20(4):299-303. PubMed ID: 27344536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward.
    Kaidar-Person O; Roach M; Créhange G
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):600-5. PubMed ID: 23523182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionation for prostate cancer: an update.
    Tiberi D; Vavassis P; Nguyen D; Yassa M
    Expert Rev Endocrinol Metab; 2017 May; 12(3):199-205. PubMed ID: 30063454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pattern of Use of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer in New South Wales, Australia, 2008 to 2012.
    Delaney GP; Gandhidasan S; Walton R; Terlich F; Baker D; Currow D
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):266-272. PubMed ID: 27473814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
    Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
    Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.
    Moore A; Stav I; Den RB; Gordon N; Sarfaty M; Neiman V; Rosenbaum E; Goldstein DA
    J Oncol; 2019; 2019():8170428. PubMed ID: 30719039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Radiation Oncology Treatment Fractionation at a Single Academic Center, 2010 to 2020.
    Cher BAY; Dykstra M; Wang C; Schipper M; Hayman JA; Mayo CS; Jagsi R
    Adv Radiat Oncol; 2022; 7(6):101032. PubMed ID: 36072755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.